Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB(TM) platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR(R) AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This development marks a significant advancement in computational drug discovery, as the LQM platform can now process extensive datasets to predict drug properties more efficiently than traditional methods. By integrating AI-driven analysis, researchers can evaluate multiple parameters simultaneously, reducing the time and cost associated with early-stage drug development. The platform's web-based interface ensures that it is accessible to a wider range of scientists, not just those with specialized computational expertise.
The expansion of predictBBB into an LQM is particularly important for the pharmaceutical industry, where the ability to rapidly assess drug candidates can accelerate the pipeline from discovery to clinical trials. Lantern Pharma's focus on precision oncology, combined with its proprietary RADR platform, positions the company to leverage this enhanced tool for its own drug development programs, including LP-184, LP-284, and LP-300. Additionally, the platform's availability to the broader research community could foster collaborations and drive innovation in drug discovery.
Lantern Pharma is a clinical-stage precision oncology company that uses AI and machine learning to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. With Zeta.ai, Lantern’s multi-agentic AI co-scientist platform, now commercially available as a subscription-based research platform, the company has established a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more information, visit the company’s newsroom at https://ibn.fm/LTRN.
